We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+9.89%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$390M
AUM Growth
-$25.1M
Cap. Flow
+$19.9M
Cap. Flow %
5.1%
Top 10 Hldgs %
87.28%
Holding
18
New
1
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$17.7M
2
KZR
Kezar Life Sciences
KZR
+$1.52M
3
KRYS icon
Krystal Biotech
KRYS
+$654K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.7B
$131M 33.49%
2,316,447
– –
IOVA icon
2
Iovance Biotherapeutics
IOVA
$3.74B
$53.7M 13.75%
2,188,331
– –
KRYS icon
3
Krystal Biotech
KRYS
$10.6B
$36M 9.24%
895,000
+20,000
+2% +$654K
COLL icon
4
Collegium Pharmaceutical
COLL
$820M
$24.8M 6.36%
1,887,332
– –
GRTS
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$23M 5.89%
2,061,758
– –
TBIO
6
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$21.3M 5.45%
+1,682,789
New +$17.7M
TPST icon
7
Tempest Therapeutics
TPST
$17.9M
$16.1M 4.14%
7,162
– –
ALNA
8
DELISTED
Allena Pharmaceuticals
ALNA
$13.6M 3.47%
3,330,373
– –
ALPN
9
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.8M 2.77%
2,571,450
– –
APTX
10
DELISTED
Aptinyx Inc. Common Stock
APTX
$10.7M 2.73%
3,190,079
– –
ITRM
11
DELISTED
Iterum Therapeutics
ITRM
$10.6M 2.71%
102,554
– –
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$10.3M 2.65%
17,026
– –
ETTX
13
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$8.71M 2.23%
1,349,953
– –
SYBX
14
DELISTED
Synlogic
SYBX
$7.88M 2.02%
57,694
– –
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.54M 1.16%
202,803
– –
KZR
16
DELISTED
Kezar Life Sciences
KZR
$3.61M 0.92%
46,774
+9,766
+26% +$1.52M
CDTX
17
DELISTED
Cidara Therapeutics
CDTX
$2.21M 0.57%
65,613
– –
BLCM
18
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.79M 0.46%
105,144
– –

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q2 2019 Portfolio in Review

As of Q2 2019, Frazier Management held 18 positions worth $390M, down 6.1% from $415M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Frazier Management deployed $19.9M of net new capital in Q2 2019, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Translate Bio, Inc. Common Stock: 1,682,789 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Frazier Management's largest Q2 2019 buy was Translate Bio, Inc. Common Stock: 1,682,789 shares worth $21.3M.
  • Frazier Management added most to Kezar Life Sciences in Q2 2019, an estimated $1.52M increase.
  • Frazier Management's ten largest holdings make up 87% of its $390M portfolio in Q2 2019.
  • Frazier Management opened 1 new position and closed 0 in Q2 2019.
  • Frazier Management's portfolio value fell 6.1% quarter-over-quarter to $390M.

Based on Frazier Management's 13F filing for Q2 2019, filed 14 Aug 2019.